Medios（MEDO.F）株式概要メディオスAGはその子会社とともに、主にドイツで特殊医薬品を供給している。 詳細MEDO.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績2/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より59.6%で取引されている 収益は年間34.03%増加すると予測されています リスク分析株式の流動性は非常に低い 過去1年間で株主の希薄化が進んだ すべてのリスクチェックを見るMEDO.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,957 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,957 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$13.6427.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m2b2016201920222025202620282031Revenue €2.4bEarnings €24.2mAdvancedSet Fair ValueView all narrativesMedios AG 競合他社Henry ScheinSymbol: NasdaqGS:HSICMarket cap: US$9.7bViemed HealthcareSymbol: NasdaqCM:VMDMarket cap: US$447.4mAunaSymbol: NYSE:AUNAMarket cap: US$384.1mNRC HealthSymbol: NasdaqGS:NRCMarket cap: US$418.7m価格と性能株価の高値、安値、推移の概要Medios過去の株価現在の株価€13.6452週高値€13.6452週安値€13.64ベータ1.081ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-72.72%最新ニュースお知らせ • Jun 30Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbHMedios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.お知らせ • Apr 30Medios AG, Annual General Meeting, Jun 10, 2026Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.お知らせ • Dec 05+ 3 more updatesMedios AG to Report Q1, 2026 Results on May 12, 2026Medios AG announced that they will report Q1, 2026 results on May 12, 2026お知らせ • Apr 15Medios AG, Annual General Meeting, May 27, 2025Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jun 08Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024.お知らせ • Mar 20Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban.最新情報をもっと見るRecent updatesお知らせ • Jun 30Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbHMedios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.お知らせ • Apr 30Medios AG, Annual General Meeting, Jun 10, 2026Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.お知らせ • Dec 05+ 3 more updatesMedios AG to Report Q1, 2026 Results on May 12, 2026Medios AG announced that they will report Q1, 2026 results on May 12, 2026お知らせ • Apr 15Medios AG, Annual General Meeting, May 27, 2025Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time.お知らせ • Jun 08Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024.お知らせ • Mar 20Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban.お知らせ • Jan 06Medios AG, Annual General Meeting, Jun 26, 2024Medios AG, Annual General Meeting, Jun 26, 2024.お知らせ • Dec 08+ 1 more updateMedios AG to Report Q2, 2024 Results on Aug 13, 2024Medios AG announced that they will report Q2, 2024 results on Aug 13, 2024株主還元MEDO.FUS HealthcareUS 市場7D0%-1.4%1.0%1Yn/a46.3%19.1%株主還元を見る業界別リターン: MEDO.FがUS Healthcare業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MEDO.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MEDO.F's price volatile compared to industry and market?MEDO.F volatilityMEDO.F Average Weekly Movementn/aHealthcare Industry Average Movement7.4%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: MEDO.F 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のMEDO.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a500Matthias Gaertnerwww.medios.agメディオスAGは子会社とともに、主にドイツで特殊医薬品を供給している。医薬品供給部門と患者別治療部門を通じて事業を展開している。医薬品供給事業では、がん、神経、自己免疫、眼科、感染症、血友病に関する製品を提供している。患者別治療薬事業では、薬局に代わって患者向けの医薬品を製造している。このセグメントには、細胞静注製剤、抗体療法、ウイルス静注製剤、抗生物質製剤、非経口栄養剤、治験薬などが含まれる。メディオスAGは2016年に設立され、ドイツのベルリンに本社を置いている。もっと見るMedios AG 基礎のまとめMedios の収益と売上を時価総額と比較するとどうか。MEDO.F 基礎統計学時価総額US$488.08m収益（TTM）US$19.43m売上高(TTM)US$1.96b25.1xPER（株価収益率0.2xP/SレシオMEDO.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MEDO.F 損益計算書（TTM）収益€1.81b売上原価€1.70b売上総利益€107.44mその他の費用€89.47m収益€17.97m直近の収益報告Mar 31, 2024次回決算日Aug 13, 2024一株当たり利益（EPS）0.70グロス・マージン5.94%純利益率0.99%有利子負債／自己資本比率0%MEDO.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/07/30 17:05終値2024/05/03 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medios AG 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Michael HeiderBerenbergMichael KuhnDeutsche BankMartin ComtesseJefferies LLC7 その他のアナリストを表示
お知らせ • Jun 30Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbHMedios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.
お知らせ • Apr 30Medios AG, Annual General Meeting, Jun 10, 2026Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Dec 05+ 3 more updatesMedios AG to Report Q1, 2026 Results on May 12, 2026Medios AG announced that they will report Q1, 2026 results on May 12, 2026
お知らせ • Apr 15Medios AG, Annual General Meeting, May 27, 2025Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jun 08Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024.
お知らせ • Mar 20Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban.
お知らせ • Jun 30Medios AG Closes the Facility of Its Wholly Owned Subsidiary, Medios Solutions Aschaffenburg GmbHMedios AG is closing the facility of its wholly owned subsidiary, Medios Solutions Aschaffenburg GmbH, and consolidated patient-specific manufacturing at the remaining locations in its Germany-wide network. Production had already been relocated, and supplies to pharmacies and hospitals are guaranteed. Aschaffenburg most recently accounted for approximately 10% of the production volume of the Medios Group’s German manufacturing facilities. The measure affects 32 employees, for whom Medios is seeking to provide fair compensation. The business of patient-specific formulations is under sustained margin pressure – particularly due to price regulatory adjustments – which the company is now countering with measures to increase efficiency. In Germany, Medios operates up until now a network of six GMP manufacturing facilities for patient-specific therapies (GMP stands for “Good Manufacturing Practice,” which entails mandatory production standards and validated quality management). The Aschaffenburg site had recently been operating at below-average profitability amid declining capacity utilization. Against this backdrop, continued economic operation was no longer feasible. Structural renovation work currently required at the site has accelerated the implementation of this decision. The site closure is part of the company’s Operational Excellence Program, which aims to sustainably strengthen profitability.
お知らせ • Apr 30Medios AG, Annual General Meeting, Jun 10, 2026Medios AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
お知らせ • Dec 05+ 3 more updatesMedios AG to Report Q1, 2026 Results on May 12, 2026Medios AG announced that they will report Q1, 2026 results on May 12, 2026
お知らせ • Apr 15Medios AG, Annual General Meeting, May 27, 2025Medios AG, Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time.
お知らせ • Jun 08Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for €259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. The transaction has attractive multiple and immediately accretive to EBITDA pre and EBITDA pre margin.Jefferies LLC acted as financial advisor to Ceban. Dirk Besse and Sebastian Schwalme of Morrison & Foerster LLP acted as legal advisors for Medios AG. Danielle du Bois-Buné, Bastiaan van Rath, Hein van den Bos, Alexander Fortuin, Matthijs Dols, Maria Benbrahim, Mariëtte Vis, Chantal van Dam, Robert Masman, Tom van Duuren, Michael Schlitt, Susanne Ries, Sebastian Biller, Karolin Hiller, Fabien Roy, Falk Schöning of Hogan Lovells International Llp acted as sell-side legal advisor to Bencis Capital Partners B.V.Medios AG (XTRA:ILM1) completed the acquisition of Ceban B.V. from Bencis Capital Partners B.V. on June 6, 2024. The conditions required for the closing of the transaction were fully met. Ceban B.V. will be included in the scope of consolidation of Medios AG as of June 1, 2024.
お知らせ • Mar 20Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million on March 18, 2024. The purchase price for the transaction includes a cash component of €235.3 million and 1.7 million new Medios shares valued approx. €23.9 million. The newly issued shares will be subject to a hard lock-up period of 24 months. The purchase price is financed by Medios from existing cash and an already committed credit facility. The 1.7 million new shares will be issued out of authorized capital against contributions in kind. Ceban had a preliminary revenue of €160 million in 2023. The preliminary EBITDA-adjusted amounts to €29 million in 2023. Ceban will continue to operate under its own brand names. Ceban’s strong and experienced management team has committed to remain fully involved to further drive growth in already existing markets and in new geographies within Europe. The completion of the transaction is subject to the fulfilment of customary closing conditions. The closing of the transaction is expected for the second quarter of 2024. Jefferies LLC acted as financial advisor to Ceban.
お知らせ • Jan 06Medios AG, Annual General Meeting, Jun 26, 2024Medios AG, Annual General Meeting, Jun 26, 2024.
お知らせ • Dec 08+ 1 more updateMedios AG to Report Q2, 2024 Results on Aug 13, 2024Medios AG announced that they will report Q2, 2024 results on Aug 13, 2024
